Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto , Toronto , Canada.
Expert Opin Biol Ther. 2019 Nov;19(11):1119-1126. doi: 10.1080/14712598.2019.1659777. Epub 2019 Aug 28.
: Pembrolizumab is a novel monoclonal antibody that targets the interaction between programmed cell death protein 1 (PD-1) and its ligand (PD-L1). Pembrolizumab has shown significant clinical efficacy in Hodgkin Lymphoma (HL), but results in non Hodgkin Lymphoma (NHL) are mixed. Some NHL subtypes, which share certain genetic features with HL, such as alterations in chromosome 9p24.1 and expression of PD-L1, have shown promising responses in early phase trials. : In this review, we provide an overview of pembrolizumab as a compound, and present the available clinical efficacy and safety data in the treatment of diffuse large B cell lymphomas. : Current early phase data suggest that single agent pembrolizumab in NHL demonstrates both efficacy and a favorable safety profile. However, it is anticipated that future treatment strategies will be biomarker-driven and incorporate pembrolizumab into combination therapies with chemotherapy and/or immunotherapy agents.
派姆单抗是一种新型的单克隆抗体，可靶向程序性细胞死亡蛋白 1（PD-1）与其配体（PD-L1）之间的相互作用。派姆单抗在霍奇金淋巴瘤（HL）中显示出显著的临床疗效，但在非霍奇金淋巴瘤（NHL）中的结果则参差不齐。某些 NHL 亚型与 HL 具有某些遗传特征，例如染色体 9p24.1 的改变和 PD-L1 的表达，在早期临床试验中显示出有希望的反应。在这篇综述中，我们提供了派姆单抗作为一种化合物的概述，并介绍了其在治疗弥漫性大 B 细胞淋巴瘤中的现有临床疗效和安全性数据。目前的早期数据表明，NHL 中单用派姆单抗既具有疗效，又具有良好的安全性。然而，预计未来的治疗策略将基于生物标志物，并将派姆单抗与化疗和/或免疫治疗药物联合应用。
